Please use this identifier to cite or link to this item:
Title: Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
Authors: Gudiol, Carlota
Royo-Cebrecos, Cristina
Abdala, Edson
Akova, Murat
Álvarez, Rocío
Maestro-de la Calle, Guillermo
Cano, Angela
Cervera, Carlos
Clemente, Wanessa T
Martín-Dávila, Pilar
Freifeld, Alison
Gómez, Lucía
Gottlieb, Thomas
Gurguí, Mercè
Herrera, Fabián
Manzur, Adriana
Maschmeyer, Georg
Meije, Yolanda
Montejo, Miguel
Peghin, Maddalena
Rodríguez-Baño, Jesús
Ruiz-Camps, Isabel
Sukiennik, Teresa C
Tebe, Cristian
Carratalà, Jordi
BICAR Study Group
Keywords: ESBLs;beta-lactam/beta-lactamase inhibitors;bloodstream infection;mortality;neutropenia
metadata.dc.subject.mesh: Adult
Anti-Bacterial Agents
Cohort Studies
Enterobacteriaceae Infections
Middle Aged
beta-Lactamase Inhibitors
Issue Date: 25-Jul-2017
Abstract: β-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.
metadata.dc.identifier.doi: 10.1128/AAC.00164-17
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.